CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/27/12 | $58,000,000 |
Acadia Woods Partners Artiman Ventures Asset Management Ventures DAG Ventures Intel Capital J.P. Morgan Longitude Capital Mohr Davidow Ventures Pappas Ventures RU-COM Temasek TPG Biotech | undisclosed |
